Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Citius Pharmaceuticals Inc (CTXR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,406
  • Shares Outstanding, K 16,200
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,380 K
  • 36-Month Beta 3.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.45 +12.41%
on 09/20/18
2.52 -35.32%
on 10/02/18
+0.15 (+10.14%)
since 09/19/18
3-Month
1.12 +45.54%
on 08/08/18
3.14 -48.09%
on 08/09/18
-1.00 (-38.02%)
since 07/19/18
52-Week
1.12 +45.54%
on 08/08/18
5.49 -70.31%
on 11/09/17
-1.13 (-40.94%)
since 10/19/17

Most Recent Stories

More News
Citius Announces The Publication Of European Patent For Mino-Lok®

Citius Pharmaceuticals Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, received official notification from...

CTXR : 1.63 (-4.12%)
Citius Announces The Issuance Of The Patent On The Advanced Stability Of Mino-Lok® By USPTO

Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, received notice from MD Anderson...

CTXR : 1.63 (-4.12%)
Citius Pharmaceuticals Successfully Raises $10 Million

Citius Pharmaceuticals, Inc. ("Citius") ("Company") ("CTXR"), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company completed...

CTXR : 1.63 (-4.12%)
Citius Announces Closing of $10.0 Million Underwritten Offering Priced At-the-Market

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the closing of the previously announced...

CTXR : 1.63 (-4.12%)
Citius Announces Pricing of $10.0 Million Underwritten Offering Priced At-the-Market

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the pricing of an underwritten offering...

CTXR : 1.63 (-4.12%)
Citius Announces Key Addition to its Scientific Advisory Board

Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company, announced that Dr. Lawrence Mermel has accepted a position on the Citius Scientific Advisory Board....

CTXR : 1.63 (-4.12%)
Citius Announces $2.0 Million Registered Direct Offering Priced At-the-Market

Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into definitive agreements...

CTXR : 1.63 (-4.12%)
Citius Reports Progress in Hemorroid Treatment Program

Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company, announced that the Company is selecting a higher potency corticosteroid in its steroid/anesthetic...

CTXR : 1.63 (-4.12%)
8-K: Citius Pharmaceuticals, Inc.

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

CTXR : 1.63 (-4.12%)
8-K: Citius Pharmaceuticals, Inc.

Date of Report (Date of earliest event reported) November 6, 2017

CTXR : 1.63 (-4.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade CTXR with:

Business Summary

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered...

See More

Key Turning Points

2nd Resistance Point 1.70
1st Resistance Point 1.66
Last Price 1.63
1st Support Level 1.59
2nd Support Level 1.56

See More

52-Week High 5.49
Fibonacci 61.8% 3.82
Fibonacci 50% 3.30
Fibonacci 38.2% 2.79
Last Price 1.63
52-Week Low 1.12

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar